Market Place
Sourcing Support
Artiva Bio to Join 25th Needham Healthcare Conference
08 Apr 2026 //
GLOBENEWSWIRE
Artiva Biotherapeutics Reports 2025 Results and Updates
10 Mar 2026 //
GLOBENEWSWIRE
Artiva Bio To Join TD Cowen 46Th Health Care Conference
25 Feb 2026 //
GLOBENEWSWIRE
Artiva Bio To Present Allonk Cost-Effectiveness In Rheumatology
21 Jan 2026 //
GLOBENEWSWIRE
Artiva Biotherapeutics Presents AlloNK Data in Autoimmune Disease
12 Nov 2025 //
GLOBENEWSWIRE
Artiva Biotherapeutics Unveils Q3 Financials & Business Update
12 Nov 2025 //
GLOBENEWSWIRE
Artiva Bio Hosts Virtual Event On Initial AlloNK Data
03 Nov 2025 //
GLOBENEWSWIRE
Artiva Bio To Join Investor Conferences In November
30 Oct 2025 //
GLOBENEWSWIRE
Artiva Bio Selects RA as Lead Indication, Plans Data, Updates
16 Oct 2025 //
GLOBENEWSWIRE
Artiva Biotherapeutics to Attend Cantor Global Healthcare
25 Aug 2025 //
GLOBENEWSWIRE
Artiva Biotherapeutics Reports Q2 2025 Financial Results
06 Aug 2025 //
GLOBENEWSWIRE
Artiva Biotherapeutics at Jefferies Global Healthcare Conference
28 May 2025 //
GLOBENEWSWIRE
Artiva Shows Durable AlloNK® + Rituximab Data at ASGCT 2025
13 May 2025 //
GLOBENEWSWIRE
Artiva Biotherapeutics Reports Q1 2025 Financial Results
08 May 2025 //
GLOBENEWSWIRE
Artiva Biotherapeutics to Present Phase 1/2 Data at ASGCT Meeting
28 Apr 2025 //
GLOBENEWSWIRE
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as CMO
08 Apr 2025 //
GLOBENEWSWIRE
Artiva Biotherapeutics Reports 2024 Financial Results & Highlight
24 Mar 2025 //
GLOBENEWSWIRE
Artiva To Join TD Cowen 45th Annual Health Care Conference
20 Feb 2025 //
GLOBENEWSWIRE
Artiva Bio Expands Board of Directors with Appointment of Dan Baker
29 Jan 2025 //
GLOBENEWSWIRE
Artiva Biotherapeutics Reports Q3 2024 Financial Results
12 Nov 2024 //
GLOBENEWSWIRE
Artiva Bio to Participate in Jefferies London Healthcare Conference
11 Nov 2024 //
GLOBENEWSWIRE
Artiva Biotherapeutics Appoints Alison Moore To Board
22 Oct 2024 //
GLOBENEWSWIRE
Artiva To Participate In Cantor Healthcare Conference
10 Sep 2024 //
GLOBENEWSWIRE
Artiva Biotherapeutics Reports Q2 Financial Results and Business Highlights
29 Aug 2024 //
GLOBENEWSWIRE
Artiva upsizes IPO to $167 million as NK cell therapy biotech heads to Nasdaq
19 Jul 2024 //
FIERCE BIOTECH
Artiva Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate
16 Aug 2023 //
BUSINESSWIRE
Artiva boasts early NK cell therapy results, giving lifeline to partner Affimed
26 May 2023 //
ENDPTS
Artiva Presents Initial Data from First-in-Human Phase 1/2 Trial of AB-101
25 May 2023 //
BUSINESSWIRE
Artiva Announces of Data from First-in-Human Phase 1/2 Clinical Trial of AB-101
26 Apr 2023 //
BUSINESSWIRE
